Skip to content
MARKETS / BALCAO / ALUR
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Allurion Technologies, Inc. ALUR

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$15.2M
▼ 52.6% YoY
$-28.8M
In brief

What this company does

Our platform, the Allurion Program (the "Allurion Program"), features the world’s first and only swallowable, ProcedurelessTM intragastric balloon for weight loss (the "Allurion Smart Capsule") and offers access to artificial intelligence ("AI")-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging and video telehealth that make up the Allurion Virtual Care Suite (“VCS”). Over 200,000 patients have already been treated commercially with the Allurion Smart Capsule in over 50 countries outside of the United States. The Allurion Smart Capsule is swallowed as a capsule under the guidance of a health care provider without surgery, endoscopy, or anesthesia. We believe the proprietary technologies that differentiate the Allurion Smart Capsule enable improved safety and efficacy outcomes.

Written from the business description in Allurion Technologies, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
USD 15.2M
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 15.2 · Net income -28.8
25.0M50.0M-40.0M-80.0M2022202320242025
Compound annual growth
−38.1%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−189 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -198.0% · Net -188.8%
-50%-100%-150%2022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -42.9
-25.0M-50.0M2022202320242025

Total assetsUSD 15.8M
EquityUSD -77.2M
CashUSD 5.4M
Current ratio0.33×

Equity funds -489% of total assets.

The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022
Revenue $B0.00.00.10.1
Operating income $B−0.0−0.1−0.1−0.0
EBITDA $B−0.0−0.0−0.1−0.0
Income tax $B0.00.00.00.0
Net income $B−0.0−0.0−0.1−0.0
Free cash flow $B·−0.0−0.1−0.0
EPS, diluted $−3.81−3.20−59.38−37.75
Dividend / sh $····
Payout %····
ROE %····
Shares out B0.010.000.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 20 reconciliationsAUDITED

Reconciled in 4 of 19 fiscal years. 75 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image